Darrell R. Borger

7.7k citations

86 papers · 4.1k indexed · 1 hit paper · h-index 35

Impact in

Cancer Research top 1%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Oncology top 1%
- Pancreatic and Hepatic Oncology Research

Papers in

Cancer Research 32
- Cancer Genomics and Diagnostics 25
Oncology 44
- Colorectal Cancer Treatments and Studies 15
- HER2/EGFR in Cancer Research 9
- Pancreatic and Hepatic Oncology Research 8

Co-authors: A. John Iafrate Dora Dias‐Santagata Leif W. Ellisen Jeffrey W. Clark Eunice L. Kwak Andrew X. Zhu David P. Ryan Vikram Deshpande
Journals: Journal of Clinical Oncology (20 papers)Gynecologic Oncology (10 papers)Clinical Cancer Research (5 papers)Cancer Research (4 papers)The Oncologist (4 papers)
Partner nations: United States Belgium Romania

In The Last Decade

Darrell R. Borger

84 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping 2011 · 548 citations

Peers

Countries citing papers authored by Darrell R. Borger

Since Specialization

Citations

This map shows the geographic impact of Darrell R. Borger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrell R. Borger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrell R. Borger more than expected).

Fields of papers citing papers by Darrell R. Borger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrell R. Borger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrell R. Borger. The network helps show where Darrell R. Borger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Darrell R. Borger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Darrell R. Borger Line = papers co-authored together Darrell R. Borger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations Clinical Cancer Research ·Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric‐Bernstam, Josep Tabernero, Filip Jankú, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, P. Jayaraman, Valerie Nicolas‐Métral, M. B. Tambieva, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, José Baselga	2019	102
2	Colorectal cancer in Crohn’s colitis is comparable to sporadic colorectal cancer International Journal of Colorectal Disease ·Jochen K. Lennerz, Kimberley W. J. van der Sloot, Long P. Le, Julie M. Batten, Jae‐Young Han, Kenneth C. Fan, Corey A. Siegel, Amitabh Srivastava, Do Youn Park, Jey-Hsin Chen, Bruce E. Sands, Joshua R. Korzenik, Robert D. Odze, Dora Dias‐Santagata, Darrell R. Borger, Hamed Khalili, A. John Iafrate, Gregory Y. Lauwers	2016	24
3	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping Journal of Thoracic Oncology ·Rebecca S. Heist, Lecia V. Sequist, Darrell R. Borger, Justin F. Gainor, Ronald S. Arellano, Long P. Le, Dora Dias‐Santagata, Jeffrey W. Clark, Jeffrey A. Engelman, Alice T. Shaw, A. John Iafrate	2016	115
4	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer Cancer Discovery ·Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran	2015	138
5	HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant Gynecologic Oncology ·Whitfield B. Growdon, Jolijn W. Groeneweg, R.K. Ching Christopher, Silvio Mario Felix Dantas, Darrell R. Borger, Rosemary Tambouret, Rosemary Foster, Ahmed Chenna, Jeff Sperinde, John Winslow, Bo R. Rueda	2015	30
6	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes Journal of Molecular Diagnostics ·Eko Yudiyanto, Amir T. Fathi, Darrell R. Borger, Andrew M. Brunner, Robert P. Hasserjian, Leonora Balaj, Amy Lum, Stephen Yip, Dora Dias‐Santagata, Zongli Zheng, Long P. Le, Timothy A. Graubert, A. John Iafrate, Valentina Nardi	2015	30
7	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas Clinical Cancer Research ·Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Prof. K.S. Redekar, Nina Lelic, James C. Kim, Dora Dias‐Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah‐Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, S. Andrew	2014	130
8	Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts Clinical Cancer Research ·Jolijn W. Groeneweg, Sílvia Hernández, R.K. Ching Christopher, Silvio Mario Felix Dantas, Guseletova Nv, M.H. Szwarcman, Minji Kim, Ling Zhang, Darrell R. Borger, Rosemary Tambouret, Rosemary Foster, Bo R. Rueda, Whitfield B. Growdon	2014	19
9	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets Annals of Surgical Oncology ·Andrew X. Zhu, Darrell R. Borger, Yuhree Kim, David Cosgrove, Aslam Ejaz, Sorin Alexandrescu, Ryan T. Groeschl, Vikram Deshpande, James Lindberg, Cristina R. Ferrone, Christine Sempoux, Thomas Yau, Ronnie T.P. Poon, Irinel Popescu, Todd W. Bauer, T. Clark Gamblin, C. Liu, Robert A. Anders, Timothy M. Pawlik	2014	110
10	Genetic Mechanisms in Interval Colon Cancers Digestive Diseases and Sciences ·James M. Richter, Maria Simona Pino, Thomas R. Austin, Emily J. Campbell, Jackie Szymonifka, Andrea Russo, Theodore S. Hong, Darrell R. Borger, A. John Iafrate, Daniel C. Chung	2014	14
11	Standardized decision support in next generation sequencing reports of somatic cancer variants Molecular Oncology ·Rodrigo Dienstmann, Fei Dong, Darrell R. Borger, Dora Dias‐Santagata, Leif W. Ellisen, Long P. Le, A. John Iafrate	2014	59
12	Branched Chain In Situ Hybridization for Albumin as a Marker of Hepatocellular Differentiation The American Journal of Surgical Pathology ·Mohd Shahid, Lan-hong Su, Julie Y. Tse, Sanjay Kakar, Adrian C Bateman, Darrell R. Borger, Miguel N. Rivera, David T. Ting, Vikram Deshpande	2014	54
13	Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer Journal of Gastrointestinal Cancer ·Andrea Russo, David P. Ryan, Darrell R. Borger, Jennifer Y. Wo, Jackie Szymonifka, Wen‐Yih Liang, Eunice L. Kwak, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Jill N. Allen, Andrew X. Zhu, David L. Berger, James C. Cusack, Harvey J. Mamon, Kevin M. Haigis, Theodore S. Hong	2013	34
14	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer Annals of Oncology ·Lawrence S. Blaszkowsky, David P. Ryan, Jackie Szymonifka, Darrell R. Borger, Andrew X. Zhu, J. W. Clark, E.L. Kwak, Harvey J. Mamon, Jill N. Allen, Hayer Georg, Paul C. Shellito, James C. Cusack, David L. Berger, Theodore S. Hong	2013	21
15	Activation of PI3K Signaling in Merkel Cell Carcinoma Clinical Cancer Research ·Valentina Nardi, Youngchul Song, Juan A. Santamaria‐Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, M.H. Szwarcman, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, A. John Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias‐Santagata	2012	87
16	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer ·Andrew X. Zhu, Thomas A. Abrams, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Hui Zheng, Alona Muzikansky, Jeffrey W. Clark, Eunice L. Kwak, Deborah Schrag, J.M Babajide, Charles S. Fuchs, A. John Iafrate, Darrell R. Borger, David P. Ryan	2011	163
17	Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells Reproductive Biology and Endocrinology ·Anne M. Friel, Lingling Zhang, Michael D. Curley, Naura Tsabita, Petra Sergent, Жондорова Галина Егоровна, Darrell R. Borger, Gayatry Mohapatra, Lawrence Zukerberg, Rosemary Foster, Bo R. Rueda	2010	47
18	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Molecular Medicine ·Dora Dias‐Santagata, Sara Akhavanfard, Madeleine A. Fidell, Agricola Batudahue Limitada, Georgiana Kuhlmann, La Ode Purnama Hamid, Hannah Stubbs, Ultan McDermott, Jeffrey Settleman, Eunice L. Kwak, Jeffrey W. Clark, Steven J. Isakoff, Lecia V. Sequist, Jeffrey A. Engelman, Thomas J. Lynch, Daniel A. Haber, David N. Louis, Leif W. Ellisen, Darrell R. Borger, A. John Iafrate	2010	282
19	Decreased survival in EGFR gene amplified vulvar carcinoma Gynecologic Oncology ·Whitfield B. Growdon, La Ode Purnama Hamid, Sara Akhavanfard, Esther Oliva, Dora Dias‐Santagata, Sakiko Kojiro, Neil S. Horowitz, A. John Iafrate, Darrell R. Borger, Bo R. Rueda	2008	46
20	Loss of Transforming Growth Factor-β (TGF-β) Receptor Type I Mediates TGF-β Resistance in Human Papillomavirus Type 16-Transformed Human Keratinocytes at Late Stages of in Vitro Progression Virology ·Yide Mi, Darrell R. Borger, Emilie Plasman, Lucia Pirisi, Hindrik de Vries	2000	20

About Darrell R. Borger

Darrell R. Borger is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Hematology, having authored 86 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (25 papers), Colorectal Cancer Treatments and Studies (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers), Glioma Diagnosis and Treatment (9 papers), HER2/EGFR in Cancer Research (9 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Genetic factors in colorectal cancer (8 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.7k citations), Genetics (651 citations), Pulmonary and Respiratory Medicine (1.2k citations) and Pathology and Forensic Medicine (585 citations). Darrell R. Borger has collaborated with scholars based in United States, Belgium and Romania. Frequent co-authors include A. John Iafrate, Dora Dias‐Santagata, Leif W. Ellisen, Jeffrey W. Clark, Eunice L. Kwak, Andrew X. Zhu, David P. Ryan, Vikram Deshpande, David N. Louis and Jeffrey A. Engelman. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Clinical Cancer Research, Cancer Research and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact